GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseBio Pharmaceuticals Inc (OTCPK:PHASQ) » Definitions » Shiller PE Ratio

PHASQ (PhaseBio Pharmaceuticals) Shiller PE Ratio : (As of Jul. 23, 2025)


View and export this data going back to 2018. Start your Free Trial

What is PhaseBio Pharmaceuticals Shiller PE Ratio?

PhaseBio Pharmaceuticals does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


PhaseBio Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for PhaseBio Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseBio Pharmaceuticals Shiller PE Ratio Chart

PhaseBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Get a 7-Day Free Trial - - - - -

PhaseBio Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Apr24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PhaseBio Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, PhaseBio Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhaseBio Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseBio Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where PhaseBio Pharmaceuticals's Shiller PE Ratio falls into.


;
;

PhaseBio Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

PhaseBio Pharmaceuticals does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.


PhaseBio Pharmaceuticals  (OTCPK:PHASQ) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


PhaseBio Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of PhaseBio Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PhaseBio Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1 Great Valley Parkway, Suite 30, Malvern, PA, USA, 19355
PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.
Executives
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Glen Burkhardt officer: VP, Human Resources C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY.,SUITE 30, MALVERN PA 19355
Jonathan Birchall officer: Chief Commercial Officer C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN PA 19355
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Clay Thorp director C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Edmund Harrigan director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Peter Justin Klein director 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
David James Ballance officer: VP, Research and Sci. Affairs C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Michael York officer: VP, Corporate Development C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
John Sang Lee officer: Chief Medical Officer C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Susan Elizabeth Arnold officer: VP, Preclinical and Chem C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY DRIVE, SUITE 30, MALVERN PA 19355
Kristopher Hanson officer: VP, Head of Legal C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355